healthcare

healthcare Articles

Tilray shares got a boost after the cannabis firm released its most recent quarterly results after the markets closed on Monday.
Dermira shares more than doubled on Monday after the firm announced midstage results from its Eczema study.
PhaseBio shares more than doubled on Monday after the firm released results from an early-stage clinical trial of its antiplatelet reversal agent.
Karyopharm shares jumped on Friday after the firm announced an FDA update from the FDA on its treatment for myeloma.
Johnson & Johnson shares dipped on Thursday on news that a California jury awarded $29 million to a woman that claimed its talcum-powder-based products caused her cancer.
Aurora Cannabis is hoping to work collaboratively with notorious activist investor Nelson Peltz to strategically explore potential partnerships. shares jumped early on Wednesday after the Cannabis...
In a new research report, RBC did some intense digging in the small-cap arena and came up with some fascinating research. These are five top small-cap growth plays suited for aggressive accounts.
Patients suffering anemia due to chronic kidney disease are sure to be content with new positive top-line results from two Phase 3 active-controlled pivotal studies.
The February 28 short interest data have been compared with the previous figures, and short interest moves in these selected marijuana stocks were mixed.
The February 28 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
In an incredible move for adolescent patients 12 to 17 years of age, the U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for with moderate-to-severe atopic dermatitis.
Tonix Pharma shares made a solid gain on Monday after the firm announced that it is beginning to enroll patients in its late-stage study of Tonmya for the treatment of post-traumatic stress disorder.
Axovant Sciences has produced results from two separate studies related to neurodegenerative diseases, and its shares had a sharp gain to start off the week.
Tonix Pharma shares spiked on Friday after the firm announced that it received a patent from the European Patent Office for its “Method for Treating Neurodegenerative Dysfunction.”